Vyome Holdings, Inc. · NASDAQ:HIND
Vyome — ReShape Lifesciences — Merger or Acquisition (July 2025)
14 slides from Vyome's merger presentation, Jul 15, 2025
Slide 1: A US-India healthcare platform with clinical-stage immuno-inflammation assets
Vyome A US-India healthcare platform with clinical-stage immuno-inflammation assets PENDING MERGER $RSLS TO $HIND CORPORATE PRESENTATION JULY 2025
Slide 2: Forward-looking statements disclaimer
VYOME THERAPEUTICS, INC. (“Vyome”) Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “belie
Slide 3: Vyome is building a 3-pillared healthcare platform in the US-India innovation corridor
Vyome is building a 3-pillared healthcare platform in the US-India innovation corridor We intend to list on Nasdaq via reverse merger with $RSLS under the ticker $HIND We have invested nearly a decade and millions of dollars to build a set of immuno-inflammatory assets with several 12-24 month catal
Slide 4: Transforming healthcare based on world-class science and talent leveraging the US-India corridor
At Vyome, we are passionate about transforming healthcare based on world-class science & talent leveraging the US-India innovation corridor Pharma Medical devices AI in healthcare VYOME HOLDINGS ($RSLS -> $HIND) US INDIA 4 Vyome has a 3-pillar plan and it intends to build, acquire, or partner with a
Slide 5: Why invest in Vyome?
1 2 3 Lower-risk biotech assets with significant catalysts in the next 12-24 months Compelling valuation based on comparable transactions; no debt Powerful US-India value capture opportunity at the optimal time • Vyome has been developing Indian research talent for a decade • US-India relationship e
Slide 6: US-India special relationship unlocks capital markets and innovation opportunity
US-India special relationship and our positioning unlocks significant capital markets and innovation opportunity Act on emerging health tech opportunities through deal-making Create cost arbitrage opportunities for capital efficiency Access capital markets looking for plays on US/India innovation 6
Slide 7: Current biotech assets offer a low-risk way to unlock significant value
The current biotech assets offer a low-risk way to unlock significant value over the next 12-24 months Malignant Fungating Wound Uveitis (steroid replacement) Inflammatory acne* $2.5B1 Market size $6M Capital required 2027 Potential value inflection timeline $2.6B2 $3M $6.0B3 - (pivotal data) by 203
Slide 8: What is MFW?
What is MFW? MFW is a non-healing wound that occurs when cancer breaks through the skin, causing infection and inflammation. Patients suffer from extreme odor, pain, low self-esteem, and social isolation. MFW afflicts ~10%* of terminal cancer patients & generates a strong odor that dramatically impa
Slide 9: Biotech asset areas form a pipeline addressing large unmet markets
Vyome’s 2 biotech asset areas form a pipeline addressing large unmet markets Use an unmet orphan indication for low-risk and cost-efficient development to open larger opportunities Our strategy Pivotal studies in 2024 MFW A DNA Gyr/MD2-TLR inhibitor Potential FDA filing for MFW in 2027 Topical infla
Slide 10: Focused on unlocking multiple value inflection points over the next 12-24 months
Vyome is focused on unlocking multiple value inflection points from its core pharma assets over the next 12-24 months MFW Program (anticipated milestones) Uveitis Program (anticipated milestones) Q3 2025 Q4 25/Q1 26 Q2 2026 Q3 2026 Q2 2027 Q3 2027 Appointment of CRO for pivotal study. Full readout o
Slide 11: Compelling entry valuation, no debt, and attractive market tailwinds
Vyome has a compelling entry valuation, no debt, and capitalizes on attractive market tailwinds merger valuation1 $120M Average market cap. of public comparables2 $800M+ debt $0M Key investment themes: • Healthcare • India – US Partnership • Next-Gen Innovation • Global Macro 4 Notes and Sources: 11
Slide 12: Public comparables footnotes
Stage / Phase, Modality, and Market Size refer to that of the Company’s Lead Program / Platform. 1) Vyome Therapeutics, Inc. market capitalization is based on the implied value in Definitive Merger Agreement with ReShape Lifesciences Inc. 2) Apogee Therapeutics Corporate Presentation July 7, 2025 -
Slide 13: Acquisition comparables footnotes
1) Represents the market capitalizations on the trading day before it was announced that each respective company was to be acquired, unless otherwise noted. 2) Vyome Therapeutics, Inc. market capitalization is based on the implied value in Definitive Merger Agreement with ReShape Lifesciences Inc. 3
Slide 14: Ideal team to execute its plan
Vyome has an ideal team to execute its plan Deep expertise in building and scaling companies; scientific thought leaders in drug development; extensive US-India crossborder experience Dr. S Sengupta,Ph.D Venkat Nelabhotla Krishna Gupta Mohanjit Jolly Co-Founder CEO & Co-Founder Chairman Board Member
ReShape Lifesciences — Merger or Acquisition (July 2025) on 6ix